Sir Alasdair Breckenridge made chair new advisory committee
This article was originally published in Scrip
Sir Alasdair Breckenbridge has been confirmed as chair of the newly established Emerging Science and Bioethics Advisory Committee, which will provide advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. Sir Alasdair is also chair of the MHRA, and previously chaired the Committee on Safety of Medicines, the North West Regional Health Authority and the Joint Committee of Higher Medical Training. His appointment is for two years.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.